Briefs: AstraZeneca Pharma India, Pharmaids and Dr. Agarwal's Health Care
AstraZeneca Pharma India discontinues manufacturing of Imdur
AstraZeneca Pharma India discontinues manufacturing of Imdur
Subcutaneous pembrolizumab administered every six weeks with a median injection time of two minutes, in combination with chemotherapy, shows consistent results across reported efficacy and safety endpoints compared to IV KEYTRUDA in combination with chemotherapy
Lexicon Pharmaceuticals announces exclusive license agreement with Novo Nordisk for LX9851
The freshly infused capital will primarily be deployed towards expansion and research & development
Adults taking Mounjaro with diet and exercise in a controlled clinical trial lost on average 21.8 kg at the highest dose (15mg) and 15.4 kg at the lowest dose (5mg)
PCC has secured the commercialization rights for the EU, UK, and Norway and will be responsible for distributing Neoatricon in these regions
The product is being recalled because the infusion bag is incorrectly labeled as Levetiracetam in 0.82% Sodium Chloride Injection 500 mg/100 mL single-dose bag, while the aluminum overwrap packaging correctly identifies the product as Levetiracetam in 0.75% Sodium Chloride Injection 1,000 mg/100 m
This expanded partnership helps Evonik to streamline its distribution model in Asia Pacific
The programme will take place on the 2nd Sunday of every month
Subscribe To Our Newsletter & Stay Updated